Scientists at Cambridge have demonstrated a new method for potentially fighting a form of leukemia, by targeting overactive enzymes that can lead to the disease. If the results of mice tests carry ...
Recent evidence suggests that natural products are much more than simply agents of “microbial warfare” and actually play critical roles in bacterial pathogenesis and communication. In particular, ...
Prague, Czech Republic: Preliminary trials of a MEK enzyme inhibitor have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Tests showed that ...
(PHILADELPHIA) – Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that ...
Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...
An effective treatment could be found for one of the most aggressive pediatric cancers, alveolar rhabdomyosarcoma (aRMS). These kinds of tumors, which develop mainly in skeletal muscle, are ...
VANCOUVER, BC / ACCESS Newswire / November 18, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it is ...
Clinical Trials Arena on MSN
Roche sizes up first BTK inhibitor approval on Phase III MS victory
If fenebrutinib got the FDA go-ahead, it would become the first BTK inhibitor to gain approval in both RMS and PPMS.
Atrial fibrillation, or AFib, is the most common heart rhythm disorder. With AFib, the beating of the upper chambers of your heart (the atria) becomes irregular, and blood has a harder time reaching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback